Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not ...

Agentic suite that streamlines AML case handling, standardizes investigations, and generates regulator-ready reports, ...

Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...

A demonstrated 100% concordance between biomarker-guided predictions from pre-treatment patient samples and clinical outcomes ...

Traditional AML and KYC processes are frequently alert-driven, resource-intensive, and constrained by human throughput.